Jerrold Dotson Net Worth

The estimated Net Worth of Jerrold Duane Dotson is at least $989 millier dollars as of 11 January 2022. Mr. Dotson owns over 18,750 units of Vistagen Therapeutics stock worth over $297,899 and over the last 8 years he sold VTGN stock worth over $93,900. In addition, he makes $597,071 as Chief Financial Officer, Vice President et Secretary at Vistagen Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dotson VTGN stock SEC Form 4 insiders trading

Jerrold has made over 3 trades of the Vistagen Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 18,750 units of VTGN stock worth $18,750 on 11 January 2022.

The largest trade he's ever made was exercising 89,742 units of Vistagen Therapeutics stock on 30 June 2021 worth over $84,357. On average, Jerrold trades about 6,925 units every 10 days since 2016. As of 11 January 2022 he still owns at least 94,571 units of Vistagen Therapeutics stock.

You can see the complete history of Mr. Dotson stock trades at the bottom of the page.

Jerrold Dotson biography

Jerrold D. Dotson CPA serves as Chief Financial Officer, Vice President, Secretary of the Company. Mr. Dotson has served as our Chief Financial Officer since September 2011, as our Corporate Secretary since October 2013 and as a Vice President since February 2014. Mr. Dotson served as Corporate Controller for Discovery Foods Company, a privately held Asian frozen foods company from January 2009 to September 2011. From February 2007 through September 2008, Mr. Dotson served as Vice President, Finance and Administration (principal financial and accounting officer) for Calypte Biomedical Corporation (OTCBB: CBMC), a publicly held biotechnology company. Mr. Dotson served as Calypte’s Corporate Secretary from 2001 through September 2008. He also served as Calypte’s Director of Finance from January 2000 through July 2005 and was a financial consultant to Calypte from August 2005 through January 2007. Prior to joining Calypte, from 1988 through 1999, Mr. Dotson worked in various financial management positions, including Chief Financial Officer, for California & Hawaiian Sugar Company, a privately held company. Mr. Dotson is licensed as a CPA in California and received his B.S. degree in Business Administration with a concentration in accounting from Abilene Christian College.

What is the salary of Jerrold Dotson?

As the Chief Financial Officer, Vice President et Secretary of Vistagen Therapeutics, the total compensation of Jerrold Dotson at Vistagen Therapeutics is $597,071. There are 3 executives at Vistagen Therapeutics getting paid more, with Shawn Singh having the highest compensation of $933,667.

How old is Jerrold Dotson?

Jerrold Dotson is 67, he's been the Chief Financial Officer, Vice President et Secretary of Vistagen Therapeutics since 2014. There are 6 older and 9 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.

What's Jerrold Dotson's mailing address?

Jerrold's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vistagen Therapeutics

Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore et Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.

What does Vistagen Therapeutics do?

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Complete history of Mr. Dotson stock trades at Vistagen Therapeutics

Vistagen Therapeutics executives and stock owners

Vistagen Therapeutics executives and other stock owners filed with the SEC include:

• Shawn Singh,
  Chief Executive Officer, Director
• Shawn K. Singh J.D.,
  CEO & Director
• H. Ralph Snodgrass,
  President, Founder, Chief Scientific Officer, Director
• Jerrold Dotson,
  Chief Financial Officer, Vice President, Secretary
• Mark Smith,
  Chief Medical Officer
• Dr. Mark A. Smith M.D., Ph.D.,
  Chief Medical Officer
• Dr. H. Ralph Snodgrass Ph.D.,
  Founder, Pres & Chief Scientific Officer
• Jerrold D. Dotson CPA, CPA,
  CFO, VP & Sec.
• Mark McPartland,
  Vice President - Corporate Development
• Jon Saxe,
  Independent Chairman of the Board
• Ann Michelle Cunningham M.B.A.,
  Chief Commercial Officer & Director
• Valter Pinto,
  Investor Relations
• Brian Underdown,
  Independent Director
• Jerry Gin,
  Independent Director
• Ann Cunningham,
  Independent Director
• Dr. Mark J. Ginski,
  Sr. VP and Head of Chemistry, Manufacturing & Controls
• Mark Adrian McPartland,
  VP of Corp. Devel.
• Healthcare Capital Partners...,
  
• Margaret M Fitz Patrick,
  
• Joanne Curley,
  
• Mary L. Rotunno,
  
• Mark J Ginski,
  SENIOR VP, HEAD OF CMC
• Joshua S. Prince,
  Chief Operating Officer
• Cynthia Lynn Anderson,
  CHIEF FINANCIAL OFFICER
• Capital Lp Commodore,
  10% owner
• Reid G. Adler,
  CHF CORP DEVEL OFF, GEN COUNS